4.6 Article

Cutting Edge: miR-223 and EBV miR-BART15 Regulate the NLRP3 Inflammasome and IL-1β Production

Journal

JOURNAL OF IMMUNOLOGY
Volume 189, Issue 8, Pages 3795-3799

Publisher

AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1200312

Keywords

-

Categories

Funding

  1. National Health and Medical Research Council Overseas Biomedical Fellowship [516783]
  2. Victorian Endowment for Science, Knowledge and Innovation Fellowship
  3. Arthritis Research United Kingdom Career Development Grant
  4. Oliver Bird Foundation
  5. Science Foundation Ireland
  6. Versus Arthritis [19213] Funding Source: researchfish

Ask authors/readers for more resources

Although microRNA (miRNA) regulation of TLR signaling is well established, this has not yet been observed for NLR proteins or the inflammasomes they form. We have now validated a highly conserved miR-223 target site in the NLRP3 3'-untranslated region. miR-223 expression decreases as monocytes differentiate into macrophages, whereas NLRP3 protein increases during this time. However, overexpression of miR-223 prevents accumulation of NLRP3 protein and inhibits IL-1 beta production from the inflammasome. Virus inhibition of the inflammasome is an emerging theme, and we have also identified an EBV miRNA that can target the miR-223 binding site in the NLRP3 3'-untranslated region. Furthermore, this virus miRNA can be secreted from infected B cells via exosomes to inhibit the NLRP3 inflammasome in noninfected cells. Therefore, we have identified both the first endogenous miRNA that limits NLRP3 inflammatory capacity during myeloid cell development and also a viral miRNA that takes advantage of this, limiting inflammation for its own purposes. The Journal of Immunology, 2012, 189: 3795-3799.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available